Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomy
Meera R. Chappidi(Johns Hopkins University), Trinity J. Bivalacqua(University of Pennsylvania), Hiten D. Patel(Northwestern University), Nikolai A. Sopko(Johns Hopkins University), Danny Lascano(University of Southern California), Jen-Jane Liu(Johns Hopkins University), Jeffrey J. Tosoian(Johns Hopkins University), Max Kates(Duke Medical Center), Deborah R. Kaye(Johns Hopkins University)
Urologic Oncology Seminars and Original Investigations
February 15, 2016
Cited by 130
Related Papers
Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress
|New England Journal of Medicine|2005|3.1k
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Priapism: Pathogenesis, Epidemiology, and Management
|The Journal of Sexual Medicine|2010|401
RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: A mechanism for diabetes-associated erectile dysfunction
|Proceedings of the National Academy of Sciences|2004|316
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
|European Urology|2014|297